Eli Lilly Enters the Vaccine Arena

Pipeline comparison: new entrant vs. established players

Active clinical programmes only (Ph.1 – Ph.3); excludes commercial & registration. Data verified May 2026.

61
total active
clinical programmes
8
companies
tracked
3
Lilly programmes
(3 acquisitions)
0
Lilly Ph.3
assets (for now)
Active clinical programmes by phase
Moderna
23.0% of total
383
14
Sanofi Pasteur
19.7% of total
543
12
GSK
16.4% of total
2242
10
Pfizer
16.4% of total
325
10
BioNTECH SE
13.1% of total
422
8
Merck & Co
4.9% of total
12
3
Eli Lilly†
4.9% of total
21
3
AZ (Icosavax)
1.6% of total
1
1
Phase 1 / Ph.1-ready Phase 1/2 Phase 2 Phase 3

† New entrant: all Lilly programmes acquired via M&A — Curevo, LimmaTech, Vaccine Company.

Key observations

  • Lilly enters via bolt-on M&A

    All three Lilly programmes were acquired in 2026: Curevo (VZV, Phase 2), LimmaTech (S. aureus, Phase 1), and Vaccine Company (EBV, Phase 1-ready). Zero internal discovery spend required to build the pipeline. The buy-not-build pattern mirrors Lilly's broader business-development posture across other modalities.

  • Pre-Phase 3 skew signals option-value strategy

    Lilly holds no Phase 3 vaccine assets. Contrast Pfizer's 5 Phase 3 programmes or Moderna's 3 Phase 3 plus 8 Phase 2. Lilly retains flexibility to accelerate any single asset, partner on others, or divest — characteristic of an early-portfolio incubator stance rather than a commercial launch posture.

  • Incumbents command 85% of tracked pipeline volume

    The top five incumbents (Moderna, Sanofi Pasteur, GSK, Pfizer, BioNTECH) account for 54 of 61 active programmes — 85.2%. Lilly's 4.9% share is identical to Merck's, but the trajectory matters: a multi-billion-dollar buyer with no legacy vaccine franchise is a different competitive presence than a legacy player thinning its portfolio.